The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives announced at its last results statement. These included deepening and adding to relationships with current and potential users of its Virtual Tumour predictive software and the intention to explore opportunities in immune-oncology and personalised medicine.
17 Jan 2017
Progress on strategic objectives
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progress on strategic objectives
Physiomics Plc (PYC:LON) | 1.6 0 14.8% | Mkt Cap: 2.10m
- Published:
17 Jan 2017 -
Author:
Derren Nathan -
Pages:
6
The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives announced at its last results statement. These included deepening and adding to relationships with current and potential users of its Virtual Tumour predictive software and the intention to explore opportunities in immune-oncology and personalised medicine.